Physician profile
George Dakwar
NPI 1366609448
$60,145.14
in general payments reported to CMS, 2019-2025
46 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $691 · 2021: $1,221 · 2022: $1,772 · 2023: $1,913 · 2024: $4,789 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $8,171 · Travel and Lodging: $1,633 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,144.00 |
| Food and Beverage | $8,170.54 |
| Travel and Lodging | $1,633.28 |
| Education | $142.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17,736.32 | 2024-2025 | Interstim |
| Covidien LP | $17,431.47 | 2019 | |
| Janssen Biotech, INC. | $9,031.40 | 2019-2025 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $3,350.35 | 2019-2025 | |
| Pfizer INC. | $2,521.69 | 2019-2025 | |
| Boston Scientific Corporation | $1,961.51 | 2019-2024 | Spaceoar Vue System - 10ml, Rezum Generator |
| Astellas Pharma US INC | $1,012.79 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Dendreon Pharmaceuticals LLC | $835.22 | 2019-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $664.70 | 2021-2025 | Erleada |
| Abbvie INC. | $570.68 | 2019-2025 | Botox, Lupron Depot |
| Astrazeneca Pharmaceuticals LP | $428.71 | 2021-2025 | Lynparza |
| Axonics, INC. | $409.78 | 2021-2024 | Axonics |
| Ferring Pharmaceuticals INC. | $394.51 | 2019-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $383.90 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Myovant Sciences INC. | $352.23 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $342.27 | 2023-2025 | Eligard, Jatenzo |
| Sumitomo Pharma America, INC. | $296.49 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $270.49 | 2021-2025 | Urolift, Barrigel |
| Intuitive Surgical, INC. | $233.62 | 2019-2023 | Da Vinci Surgical System |
| Verity Pharmaceuticals INC. | $203.52 | 2022-2023 | Trelstar |
| Myriad Genetic Laboratories, INC. | $189.23 | 2020-2024 | Prolaris, Myrisk |
| Novartis Pharmaceuticals Corporation | $179.22 | 2023-2025 | |
| Immunitybio, INC. | $150.91 | 2025 | |
| Amgen INC. | $140.85 | 2019-2024 | Prolia |
| Endo Pharmaceuticals INC. | $132.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.04 | 2019-2022 | |
| Telix Pharmaceuticals | $106.44 | 2023-2025 | Illuccix |
| Blue Earth Diagnostics | $95.53 | 2020-2023 | |
| Progenics Pharmaceuticals, INC. | $79.62 | 2024-2025 | |
| Urogen Pharma, INC. | $61.47 | 2021-2025 | |
| Clinigen, INC. | $55.87 | 2019-2020 | |
| Urovant Sciences INC | $52.51 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.84 | 2019-2021 | |
| Dentsply Ih Ab | $37.07 | 2023 | Lofric |
| Procept Biorobotics Corporation | $36.39 | 2024-2025 | Aquabeam System |
| C. R. Bard, INC. & Subsidiaries | $35.69 | 2019 | |
| Coloplast Corp | $35.14 | 2022 | |
| Ambu INC. | $34.75 | 2024 | |
| Allergan, INC. | $25.11 | 2021 | |
| Accord Healthcare, INC. | $21.82 | 2023 | |
| Bioprotect Medical, INC. | $20.82 | 2024 | Bioprotect Balloon Implant System |
| Baxter Healthcare | $16.23 | 2021 | |
| Tesaro, INC. | $15.90 | 2019 | |
| Calyxo, INC. | $14.44 | 2025 | Cvac Aspiration System |
| Clovis Oncology, INC. | $13.41 | 2020 | |
| Foundation Medicine, INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dakwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.